Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited 佳兆業健康集團控股有限公司 (Incorporated in Bermuda with limited liability) (Stock Code: 876)

DELAY IN PUBLICATION OF THE AUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021

This announcement is made by Kaisa Health Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rules 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong).

As disclosed in the announcement of the Company dated 30 March 2022 in relation to the unaudited financial results of the Company for the year ended 31 December 2021, the Company will issue further announcement if there are other material developments in the completion of the auditing process in relation to the annual consolidated results for the year ended 31 December 2021 (the "**Annual Results**"). Given the auditors of the Company encountered challenges in performing the annual audit during the COVID-19 pandemic and require additional time to complete their internal audit procedures, the Company expects to publish the audited Annual Results (which have been agreed with the Company's auditors) on or before Friday, 22 April 2022. The board of directors of the Company wishes to emphasize that the operation of the Group remains normal.

A meeting of the Board will be held on the date of publication of the audited Annual Results for the purposes of, inter alia, considering and approving the same and its publication.

By order of the Board Kaisa Health Group Holdings Limited Zhang Huagang Chairman

Hong Kong, 14 April 2022

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman) and Mr. Kwok Ying Shing and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Yonglan.